View an eLearning presentation

Join for membership or sign in now to view a ∼7-minute eLearning presentation about IBD.

elearning iconJoin/Sign in
Menu

Understanding
the pathophysiology
can help bring
further clarity to IBD

Take a closer look at the
pathogenesis of IBD

View an eLearning presentation

Join for membership or sign in now to view a ∼7-minute eLearning presentation about IBD.

elearning iconJoin/Sign in

Learn about the role of lymphocyte trafficking and IBD

A multistep adhesion cascade

microscopeLearn more

Focus on the Intestinal Immune System in IBD video

Get an overview of the intricate mechanisms that mediate inflammation in the gut and the pathophysiology of IBD.

videoWatch the video

View complete references

1.Knigge KL. Inflammatory bowel disease. Clin Cornerstone. 2002;4(4):49-60.
2.Eksteen B, Liaskou E, Adams DH. Lymphocyte homing and its role in the pathogenesis of IBD. Inflamm Bowel Dis. 2008;14(9):1298-1312.
3.Crohn’s and Colitis Foundation of America. The Facts About Inflammatory Bowel Diseases. 2011. http://www.ccfa.org/assets/pdfs/
ibdfactbook.pdf
. Accessed July 15, 2013.
4.National Institute of Diabetes and Digestive and Kidney Diseases. Crohn’s disease. 2011. http://digestive.niddk.nih.gov/
ddiseases/pubs/crohns/
. Accessed March 28, 2012.
5.National Institute of Diabetes and Digestive and Kidney Diseases. Ulcerative colitis. 2011. http://digestive.niddk.nih.gov/
ddiseases/pubs/colitis/
. Accessed March 28, 2012.
6.Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347(6):417-429.
7.The Crohn’s and Colitis Foundation of Canada. The burden of inflammatory bowel disease (IBD) in Canada. 2008.
8.Centers for Disease Control and Prevention. Inflammatory bowel disease (IBD).
http://www.cdc.gov/ibd. Accessed February 13, 2012.
9.Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504-1517.
10.Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct healthcare costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135(6):1907-1913.
11.Park KT, Bass D. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. Inflamm Bowel Dis. 2011;17(7):1603-1609.
12.Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J. The costs of Crohn’s disease in the United States and other Western countries: a systematic review. Curr Med Res Opin. 2008;24(2):319-328.
13.Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31(7):693-707.
14.Canadian Digestive Health Foundation. Statistics. http://www.cdhf.ca/
digestive-disorders/statistics.shtml
. Accessed February 22, 2012.
15.Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn’s disease and ulcerative colitis. J Occup Environ Med. 2008;50(11):1261-1272.
16.Hanauer SB. Review article: aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20(Suppl 4):60-65.
17.Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E. The human glucocorticoid receptor: molecular basis of biologic function. Steroids. 2010;75(1):1-12.
18.Pithadia AB, Jain S. Treatment of inflammatory bowel disease (IBD). Pharmacol Rep. 2011;63(3):629-642.
19.Kaser A, Tilg H. Novel therapeutic targets in the treatment of IBD. Expert Opin Ther Targets. 2008;12(5):553-563.
20.Perencevich M, Burakoff R. Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(7):651-664.
21.Ginsburg PM, Bayless TM. Managing functional disturbances in patients with inflammatory bowel disease. Curr Treat Options Gastroenterol. 2005;8(3):211-221.
22.Crohn’s and Colitis Foundation of America. Diet and Nutrition. http://www.ccfa.org/info/diet. Accessed April 23, 2012.
23.Eiden KA. Nutritional considerations in inflammatory bowel disease. Pract Gastroenterol. 2003;27(5):33-54.
24.Crohn’s and Colitis Foundation of America. Surgery for ulcerative colitis. http://www.ccfa.org/info/surgery/
surgeryuc
. Accessed April 16, 2012.
25.Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(suppl 5):V1-V16.
26.Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol. 2003;3(4):331-341.
27.McGuckin MA, Eri R, Simms LA, Florin TH, Radford-Smith G. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis. 2009;15(1):100-113.
28.Adams DH, Eksteen B, Curbishley SM. Immunology of the gut and liver: a love/hate relationship. Gut. 2008;57(6):838-848.
29.Vermeire S, Van Assche G, Rutgeerts P. Inflammatory bowel disease and colitis: new concepts from the bench and the clinic. Curr Opin Gastroenterol. 2011;27(1):32-37.
30.Hanauer S. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006;12(Suppl 1):S3-S9.
31.Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427-434.
32.Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369(9573):1627-1640.
33.Koizumi M, King N, Lobb R, Benjamin C, Podolsky DK. Expression of vascular adhesion molecules in inflammatory bowel disease. Gastroenterology. 1992;103(3):840-847.
34.Crohn’s and Colitis Foundation of America. About Crohn’s disease. 2009. http://www.ccfa.org/
info/about/crohns
. Accessed March 28, 2012.
35.Salmi M, Jalkanen S. Lymphocyte homing to the gut: attraction, adhesion, and commitment. Immunol Rev. 2005;206:100-113.
36.Sheriden BS, Lefrançois L. Regional and mucosal memory T cells. Nat Immunol. 2011;12(6):485-491.
37.von Andrian UH, Mackay CR . T-cell function and migration. Two sides of the same coin.N Engl J Med. 2000;343(14):1020-1034.
38.Koenecke C, Förster R. CCR9 and inflammatory bowel disease. Expert Opin Ther Targets. 2009;13(3):297-306.
39.Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal address in cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997;151(1):97-110.
40.Yoshie O, Imai T, Nomiyama H. Chemokines in immunity. Adv Immunol. 2001;78:57-110.
41.Nishimura M, Kuboi Y, Muramoto K, Kawano T, Imai T. Chemokines as novel therapeutic targets for inflammatory bowel disease. Ann N Y Acad Sci. 2009;1173:350-356.
42.Stedman’s Medical Dictionary. 27th ed. New York, NY: Lippincott Williams & Wilkins; 2000.
43.Janeway CA Jr, Travers P, Walport M, Shlomchik MJ. Immunobiology: The Immune System in Health and Disease. 6th ed. New York, NY: Garland Science Publishing; 2005.